These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24856227)

  • 21. Prevalence of airflow limitation in subjects undergoing comprehensive health examination in Japan: Survey of Chronic Obstructive pulmonary disease Patients Epidemiology in Japan.
    Omori H; Kaise T; Suzuki T; Hagan G
    Int J Chron Obstruct Pulmon Dis; 2016; 11():873-80. PubMed ID: 27217740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of prevalent and new COPD cases in Greece: the GOLDEN study.
    Mitsiki E; Bania E; Varounis C; Gourgoulianis KI; Alexopoulos EC
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1371-82. PubMed ID: 26229456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
    Crim C; Calverley PMA; Anderson JA; Holmes AP; Kilbride S; Martinez FJ; Brook RD; Newby DE; Yates JC; Celli BR; Vestbo J;
    Respir Med; 2017 Oct; 131():27-34. PubMed ID: 28947039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale.
    Tranmer JE; Heyland D; Dudgeon D; Groll D; Squires-Graham M; Coulson K
    J Pain Symptom Manage; 2003 May; 25(5):420-9. PubMed ID: 12727039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.
    Martinez FJ; Fabbri LM; Ferguson GT; Orevillo C; Darken P; Martin UJ; Reisner C
    Chest; 2017 Dec; 152(6):1169-1178. PubMed ID: 28720336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort.
    van Dijk W; Tan W; Li P; Guo B; Li S; Benedetti A; Bourbeau J;
    Ann Fam Med; 2015; 13(1):41-8. PubMed ID: 25583891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study of the clinical phenotype of symptomatic chronic airways disease by hierarchical cluster analysis and two-step cluster analyses].
    Ning P; Guo YF; Sun TY; Zhang HS; Chai D; Li XM
    Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):679-83. PubMed ID: 27586974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-life assessment of the multidimensional nature of dyspnoea in COPD outpatients.
    Morélot-Panzini C; Gilet H; Aguilaniu B; Devillier P; Didier A; Perez T; Pignier C; Arnould B; Similowski T
    Eur Respir J; 2016 Jun; 47(6):1668-79. PubMed ID: 27076585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COPD assessment test and severity of airflow limitation in patients with asthma, COPD, and asthma-COPD overlap syndrome.
    Kurashima K; Takaku Y; Ohta C; Takayanagi N; Yanagisawa T; Sugita Y
    Int J Chron Obstruct Pulmon Dis; 2016; 11():479-87. PubMed ID: 27019598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease.
    Tabberer M; Brooks J; Wilcox T
    Health Qual Life Outcomes; 2015 Oct; 13():177. PubMed ID: 26520062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences between physician and patient in the perception of symptoms and their severity in COPD.
    Miravitlles M; Ferrer J; Baró E; Lleonart M; Galera J
    Respir Med; 2013 Dec; 107(12):1977-85. PubMed ID: 23890959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depression in patients with stable chronic obstructive pulmonary disease: a cross-sectional study in the national center for respiratory diseases in Indonesia.
    Rosrita NN; Yunus F; Ginting TT; Nurwidya F
    Pneumologia; 2016; 65(4):197-200. PubMed ID: 29542901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Johnson KM; Bryan S; Ghanbarian S; Sin DD; Sadatsafavi M
    Respir Res; 2018 Feb; 19(1):26. PubMed ID: 29415723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of serum vascular adhesion protein-1 with airflow limitation and quality of life in stable chronic obstructive pulmonary disease.
    Amani M; Ghadimi N; Aslani MR; Ghobadi H
    Respir Med; 2017 Nov; 132():149-153. PubMed ID: 29229088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ; Yoon HK; Park MJ; Yoo KH; Jung KS; Park JW; Lim SY; Shim JJ; Lee YC; Kim YS; Oh YM; Kim S; Yoo CG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1589-1596. PubMed ID: 28615931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptom Clusters and Quality of Life in Subjects With COPD.
    Lim KE; Kim SR; Kim HK; Kim SR
    Respir Care; 2017 Sep; 62(9):1203-1211. PubMed ID: 28720670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort.
    Yohannes AM; Mülerová H; Lavoie K; Vestbo J; Rennard SI; Wouters E; Hanania NA
    J Am Med Dir Assoc; 2017 Nov; 18(11):955-959.e6. PubMed ID: 28733182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis.
    Murtagh FE; Addington-Hall JM; Edmonds PM; Donohoe P; Carey I; Jenkins K; Higginson IJ
    J Palliat Med; 2007 Dec; 10(6):1266-76. PubMed ID: 18095805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impacts of morning, daytime, and nighttime symptoms on disease burden in real-world patients with COPD.
    Muñoz A; Small M; Wood R; Ribera A; Nuevo J
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1557-1568. PubMed ID: 29805254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.